Modified Parasite Drug Shows Promise for Endometriosis Treatment in Animal Tests

New Drug Test

Researchers have modified an existing anti-parasite medication called niclosamide to target cells responsible for endometriosis, a chronic condition affecting roughly 190 million people. The modified drug was tested in mice and published in the journal Advanced Healthcare Materials.

Current Treatment Limits

Endometriosis occurs when cells from the inner lining of the uterus grow outside of it, creating painful lesions. Current treatments rely heavily on surgery or hormone therapy, though both options bring significant drawbacks. Nearly half of all patients who have surgery see their lesions return within five years. Meanwhile, hormone therapies often block pregnancy and cause side effects like depression and bone thinning.

Previous Challenges

Niclosamide showed promise in reducing endometrial tissue growth in a 2016 study, but it suffered from poor water solubility. This meant patients needed high doses that triggered severe side effects like nausea and stomach cramps, limiting its approved use to just seven days.

Context

Endometriosis remains difficult to diagnose and treat partly because it often requires surgery to confirm and because menstrual pain has historically been dismissed or normalized. Finding non-surgical and non-hormonal alternatives is a major goal for reproductive health researchers seeking to improve patient quality of life.